XML 98 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
SHARE-BASED PAYMENTS (Tables)
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of share-based compensation, stock options, activity The summary of the Company’s stock options at December 31, 2021, 2020 and 2019, respectively, and the changes for the fiscal periods ending on those dates, are presented below:
 Range of Exercise PricesNumber of SharesWeighted Average
Exercise Price
Weighted Average Remaining Contractual Life (Years)Intrinsic Value
Outstanding, December 31, 2018
$1.70 - $15.61
1,732,754 $3.84 
 Granted2.92 296,450 2.92 
 Exercised
1.70 - 2.92
(54,805)2.27 
 Forfeited
1.70 - 7.42
(342,866)3.94 
 Expired6.97(144,100)6.97 
Outstanding, December 31, 2019
$1.70 - $15.61
1,487,433 $3.43 
 Granted
1.76 - 3.06
711,414 1.77 
 Exercised
1.70 - 2.92
(302,707)1.97 
 Forfeited
1.70 - 5.18
(188,541)3.26 
 Expired
4.12 - 5.22
(98,512)$4.40 
Outstanding, December 31, 2020
$1.70 - $15.61
1,609,087 $2.91 
 Granted
3.89 - 8.41
169,310 3.99 
 Exercised
1.70 - 7.42
(775,814)2.95 
 Forfeited
1.76 - 5.91
(8,048)3.16 
 Expired
1.70 - 15.61
(51,653)8.14 
Outstanding, December 31, 2021
$1.70 - $8.41
942,882 $2.79 2.50$4,565
Exercisable, December 31, 2021
$1.70 - $7.14
729,565 $2.83 2.22$3,504
Schedule of compensation costs for share-based payment arrangements
The components of share-based compensation are as follows:
Years ended December 31,
202120202019
Recognized expense
Stock options$323 $555 $453 
RSU awards (1)
1,562 1,272 2,006 
SARs273 771 1,312 
Total recognized expense$2,158 $2,598 $3,771 
(1)The fair value of the RSUs granted under the Compensation Plan for the years ended December 31, 2021, 2020 and 2019, was estimated at the date of grant, using the stated market price.
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The fair value of the stock options granted under the Compensation Plan for the years ended December 31, 2021, 2020 and 2019 was estimated at the date of grant, using the Black-Scholes Option Valuation Model, with the following weighted average assumptions:
Years ended December 31,
202120202019
Risk-free interest rate0.44 %1.27 %2.62 %
Expected life (in years)5.0 years4.6 years5.0 years
Expected volatility61.96 %61.81 %*59.38 %*
Expected dividend yield%%%
Weighted average grant date fair value$2.06 $0.82 $1.54 
* Expected volatility is measured based on the Company’s historical share price volatility over a period equivalent to the expected life of the stock options.
Schedule of share-based compensation, restricted stock and restricted stock units activity The summary of the Company’s non-vested stock options at December 31, 2021, 2020 and 2019, respectively, and the changes for the fiscal periods ending on those dates, are presented below:
 Number of SharesWeighted Average Grant Date Fair Value
Non-vested, December 31, 2018297,044 $1.06 
 Granted296,450 1.54 
 Vested(356,626)1.27 
 Forfeited(13,487)1.59 
Non-vested, December 31, 2019223,381 $1.32 
 Granted711,414 0.82 
 Vested(508,630)0.94 
 Forfeited(22,175)0.96 
Non-vested, December 31, 2020403,990 $0.94 
 Granted169,310 2.06 
 Vested(351,934)1.23 
 Forfeited(8,049)1.60 
Non-vested, December 31, 2021213,317 $1.34 
The summary of the Company’s non-vested RSUs at December 31, 2021, 2020 and 2019, respectively, and the changes for the fiscal periods ending on those dates, are presented below:
 Number of SharesWeighted Average Grant Date Fair Value
Non-vested, December 31, 20181,580,187 $1.99 
 Granted731,435 2.91 
 Vested(862,378)2.00 
 Forfeited(133,708)2.40 
Non-vested, December 31, 20191,315,536 $2.45 
 Granted740,998 1.65 
 Vested(746,477)2.45 
 Forfeited(216,001)2.13 
Non-vested, December 31, 20201,094,056 $1.98 
 Granted441,241 3.89 
 Vested(635,233)1.94 
 Forfeited— — 
Non-vested, December 31, 2021900,064 $2.94 
Share-based Payment Arrangement, Stock Appreciation Right, Activity The summary of the Company’s SARs at December 31, 2021, 2020 and 2019, respectively, and the changes for the fiscal periods ending on those dates, are presented below:
 Number of SharesWeighted Average
Exercise Price
Weighted Average Remaining Contractual Life (Years)Intrinsic Value
Outstanding, December 31, 2018— $— 
 Granted2,195,994 2.92 
 Exercised— — 
 Forfeited(30,485)2.92 
 Expired— — 
Outstanding, December 31, 20192,165,509 $2.92 
Granted— — 
Exercised— — 
Forfeited(444,886)2.92 
Expired— — 
Outstanding, December 31, 20201,720,623 $2.92 
 Granted— — 
 Exercised(48,201)2.92 
 Forfeited— — 
 Expired— — 
Outstanding, December 31, 20211,672,422 $2.92 2.06$7,877
Exercisable, December 31, 20211,098,873 $2.92 2.06$5,176
The summary of the Company’s non-vested SARs at December 31, 2021, 2020 and 2019, respectively, and the changes for the fiscal periods ending on those dates, are presented below:
 Number of SharesWeighted Average Grant Date Fair Value
Non-vested December 31, 2018— $— 
Granted2,195,994 1.25 
Vested— — 
Forfeited(30,485)1.25 
Non-vested December 31, 20192,165,509 $1.25 
Granted— — 
Vested— — 
Forfeited(444,886)1.25 
Non-vested December 31, 20201,720,623 $1.25 
 Granted— — 
 Vested(1,147,074)1.27 
 Forfeited— — 
Non-vested December 31, 2021573,549 $1.19